Archive:
Roche event at HSK: “Precision oncology: progress – for everyone, a few, or for no one?”
02.08.2023
Innovation Fund Project on Mental Illnesses (RECOVER)
02.08.2023
When you talk to Marcus Quack, the DACH managing director of Revvity, and ask him what the company, which is only a few months old, actually does, he first has to take a deep breath. The company was previously affiliated with PerkinElmer, whose applied, food and enterprise services were purchased by private equity firm New Mountain Capital for nearly $2.5 billion. The new scientific solutions company Revvity, however, continues to support pharmaceutical and biotech companies as well as diagnostic laboratories, universities and governments under a new name. “Monitor Health Services Research” spoke to Marcus Quack about the company’s rather ambitious goals and a possible link to health services research.
02.08.2023
With what is now the fourth event on the topic of vaccination, “Monitor Health Services Research” is expanding its view on the one hand to European best practice approaches and, on the other hand, to very practical findings from low-threshold vaccination offers that already exist in Germany, both in pharmacies and in companies, as well as on a wider scale, but so far not too well-known field of activity of the public health service.
02.08.2023
Comment series, part 6: Prof. Dr. rer. pole. Philip Manow, Professor of Comparative Political Economy, University of Bremen
02.08.2023
Mysterious Data Policy >> In the social sciences, the inadequate coronavirus data policy of the Robert Koch Institute (RKI) and its focus on the daily or cumulative number of confirmed COVID-19 cases were criticized, albeit only sporadically, as early as spring 2020. For example, one of Germany's leading sociologists, Rainer Schnell—together with Menno Smid of the Infas Institute […]
02.08.2023
Comment from Dr. PH Andrej Rasch, Senior Manager Benefit Assessment/HTA Coordination, Association of Research-Based Drug Manufacturers (e. V.). Topic: current BSG ruling and its consequences.
02.08.2023
The AMNOG procedure has been legally adjusted several times in recent years. A significant change recently occurred with the GKV Financial Stabilization Act (GKV-FinStG), which was passed at the end of 2022. The legal package of measures includes, among other things, new requirements for reimbursement amount negotiations, which change the basic principle of AMNOG. According to these new requirements (so-called “guardrails”), in certain cases a new drug may not cost more than the comparative therapy despite the proven additional benefit. If there is no proven additional benefit, the costs must even be lower. The details of these new requirements are subjected to a critical analysis below.